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Abstract
Background: In the developing world, the principal cause of death among HIV-infected patients is tuberculosis (TB). The
initiation of antiretroviral therapy (ART) during TB therapy significantly improves survival, however it is not known which
barriers prevent eligible TB patients from initiating life-saving ART.
Method: Setting. A South African township clinic with integrated tuberculosis and HIV services. Design. Logistic regression
analyses of a prospective cohort of HIV-1 infected adults ($18 years) who commenced TB therapy, were eligible for ART,
and were followed for 6 months.
Findings: Of 100 HIV-1 infected adults eligible for ART during TB therapy, 90 TB patients presented to an ART clinic for
assessment, 66 TB patients initiated ART, and 15 TB patients died. 34% of eligible TB patients (95%CI: 25–43%) did not
initiate ART. Male gender and younger age (,36 years) were associated with failure to initiate ART (adjusted odds ratios of
3.7 [95%CI: 1.25–10.95] and 3.3 [95%CI: 1.12–9.69], respectively). Death during TB therapy was associated with a CD4+ count
,100 cells/mL.
Conclusion: In a clinic with integrated services for tuberculosis and HIV, one-third of eligible TB patients – particularly young
men – did not initiate ART. Strategies are needed to promote ART initiation during TB therapy, especially among young
men.
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Introduction
Tuberculosis (TB) is frequently encountered in South Africa and is
associated with considerable morbidity and mortality. In 2007, the
estimated TB incidence in South Africa was 948/100,000 people in
the general population[1] – the fifth highest in the world[2]. In the
same year, it is estimated that there were 461,000 new TB cases, and
that 112,000 TB deaths occurred [1]. Co-infection with human
immunodeficiency virus type-1 (HIV-1) is responsible for this high
mortality[3]: In South Africa, co-infection occurs in 73% of people
diagnosed with TB and 84% of people who die with TB[1].
Restoring immune function with antiretroviral treatment (ART)
can reduce the high morbidity and mortality of TB. While
considerable debate exists whether ART should be commenced
early or late during TB treatment, there is compelling evidence that
ART in eligible patients should not be deferred until after TB
treatment[4].
The provision of ART to eligible TB patients during TB
treatment is clearly a priority for South Africa[5]. While little is
known about obstacles to ART initiation during TB treatment,
data exists for HIV/AIDS cohorts. Losina et al report that almost
50% of patients in their cohort did not have a CD4+ count within
8 weeks of HIV diagnosis [6]. Moreover, up to 2 months may
elapse between obtaining the initial CD4 count and first ART
training (7). These delays are concerning, especially as a
substantial proportion of HIV-related morbidity and mortality
occurs after 2 months of TB therapy[4,8].
Timely initiation of ART requires efficient assessment of eligible
TB patients, as well as elimination of barriers to ART initiation.
Here, we performed a secondary analysis of a recently-described
prospective cohort of HIV-1 infected TB patients[8] in order to
determine the barriers to ART initiation.
Methods
Study population
We conducted our study in a high density (.7500 inhabitants/
km2), predominantly black township in South Africa [9], where
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TB case notification rates approach 1,600/100,000 people of the
general population annually. TB patients in this township are
treated in TB clinics administered by Cape Town’s Health
Department. According to national protocol, TB patients receive
standardized TB treatment regimens using Directly Observed
Therapy Short-course (DOTS)[10]. National guidelines recom-
mended ART for all TB patients with a CD4+ cell count less than
200 cells/mL or a history of a WHO stage 4 illness[10]. Extra-
pulmonary tuberculosis – although a WHO stage 4 illness – was
not an indication for ART unless the patient’s CD4+ count was less
than 200 cells/mL. First-line ART during our study was stavudine,
lamivudine, and either nevirapine or efavirenz. Efavirenz was
preferred for adults receiving rifampin-based TB treatment.
National guidelines also recommended daily trimethoprim-sulfa-
methoxazole (160/800 mg) chemoprophylaxis[9].
Our study center is one of the first in South Africa to
successfully integrate ART and TB health-care services. As a
result, our TB cohort is characterised by high rates of i) voluntary
counselling and testing of HIV status (.95%), ii) rigorous testing
of CD4+ counts if HIV-infected (<99%), and iii) provision of
trimethoprim-sulfamethoxazole chemoprophylaxis (.95%)[8].
Moreover, DOTS coverage is .80% at this center (personal
communication –Judy Caldwell, Cape Town Health Department).
We have previously described our prospective cohort of 209
HIV-infected TB patients ($18 years of age), which were recruited
at our study center. Data obtained from this cohort was used to
determine the incidence, risk factors and causes of clinical
deterioration during 6 months of TB therapy[8]. All adults in
our cohort were recruited at initiation of TB therapy – regardless
of HIV status – and followed for 6 months. Written informed
consent was obtained from enrolled adults and the Research
Ethics Committee of the University of Cape Town approved this
study (REC 178/2008).
The following is a secondary analysis of this cohort: among
those eligible to receive ART, we determined factors associated
with not initiating ART. Of 209 enrolled HIV-infected TB
patients (figure 1), 100 comprised our study population as they
were eligible to initiate ART at TB diagnosis, according to
national guidelines. Reasons for excluding the remaining 109 TB
patients are shown in figure 1: CD4+ count not performed (n = 3),
ART started prior to TB treatment (n = 33), transferred out
(n = 13), ineligible for ART as CD4+ count greater than 200 cells/
mL (n= 49) and lost to follow-up (n = 11). We defined ‘transferred
out’ as transfer of care to another tuberculosis clinic at a patient’s
request. This transfer was facilitated by a written referral letter and
resulted in exclusion from our study. We defined ‘lost to follow-up’
as being unable to trace a TB patient 6 months after commencing
TB treatment. We used clinic and hospital charts, as well as the
Provincial Government of the Western Cape’s electronic tuber-
culosis register (ETR.net)[11] to trace TB patients and record
clinical outcomes.
We determined the proportion of eligible TB patients that did
not initiate ART during TB treatment. We also determined those
at greatest risk of i) not presenting to the ART clinic for
assessment, ii) not initiating ART, and iii) death. In our setting,
eligible TB patients were referred with a written letter to their
nearest ART clinic for assessment. TB patients who presented to
the ART clinic for assessment received ART education from
trained counsellors. After appropriate counselling and evaluation
by either a nurse or doctor, TB patients initiated ART. In our
study, a TB patient who attended one or more ART clinic
appointments was considered to have ‘presented to an ART clinic
for assessment.’ We reviewed TB patients’ hospital and ART
charts, the Western Cape’s electronic tuberculosis register
(ETR.net)[11] and Cape Town’s electronic eKapa ART database
to record those who presented to an ART clinic for assessment, as
well as those who initiated ART.
We defined clinical deterioration as symptomatic worsening or
failure to stabilise within 24 weeks following initiation of TB
treatment[8]. Causes of clinical deterioration included AIDS-
defining illnesses (according to WHO stage 4 criteria), non AIDS-
defining HIV-related infections, TB-related illnesses, and illnesses
unrelated to TB, i.e. co-morbid illnesses. These illnesses have been
described in detail in a previous report[8].
Statistical analysis
We performed statistical analysis using Stata 10.0 (Texas, USA).
We found that age, weight at TB diagnosis and duration to ART
initiation were right (non-normal) skewed but had normal
distributions with logarithmic transformation (Shapiro-Wilk test);
we described these variables using means and 95% confidence
intervals (95% CIs). The mean age was used to dichotomise age
categories (age ,36 years vs age $36 years). Proportions were
calculated for categorical variables and described using 95% CIs.
We used the Fisher exact test to determine which categorical
variables were significantly associated with i) not presenting to an
ART clinic for assessment, ii) not initiating ART and iii) death. A
p-value of less than 0.05 was considered significant.
Using logistic regression analysis, we explored relationships
between categorical variables and i) not presenting to an ART
clinic for assessment, ii) not initiating ART and iii) death.
Backward stepwise logistic models were proposed to quantify
these relationships; these models were reported using adjusted
odds ratios and 95% CIs. We fitted each model using the
likelihood ratio, which was logarithmically transformed to
generate the chi-squared statistic.
Results
Description of eligible adults in follow-up
The following features characterised the 100 eligible TB patients
at TB diagnosis (table 1): The mean age was 36 years (95% CI: 23–
57 years) and 54% (95% CI: 44–64%) were male. Men were older
than women (mean age in years, 95%CI: 37 [23–59] vs. 35 [22–55])
but this difference was not statistically significant. At TB diagnosis,
70% of TB patients had a CD4+ count less than 100 cells/mL, 30%
had a previous history of tuberculosis, 56% had no evidence of
extra-pulmonary tuberculosis and 23% had results for TB drug
susceptibility testing – most of whom were drug susceptible (87%,
20/23). During TB treatment, 95% of TB patients received
trimethoprim-sulfamethoxazole chemoprophylaxis, 66% experi-
enced clinical deterioration and 50% required hospital admission.
At 6 months of TB therapy, drug sensitive Mycobacterium tuberculosis
was cultured in 47 (88%) of 53 TB patients for whom drug
susceptibility testing was performed.
Barriers to presentation to the ART clinic for assessment
Among the 100 eligible TB patients (figure 1), 90% presented to
an ART clinic for assessment, while 10% did not. In univariate
analyses (data not shown), the following were significantly
associated with not presenting at an ART clinic for assessment:
previous tuberculosis and admission to hospital. Using our logistic
regression model, we found that previous TB remained significant
(OR=4.1, 95%CI: 1.04–16.42; Model P = 0.015, R2= 0.129).
Barriers to ART initiation
Of the 100 eligible TB patients, 66% (95%CI: 57–75%)
initiated ART during TB treatment while 34% (95%CI: 25–
Barriers to ART during TB Therapy
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43%) did not (figure 1). The mean interval from commencing TB
treatment to ART initiation was 58 days (95%CI: 18–184 days).
Of the 25 TB patients alive and not receiving ART at 6 months of
follow-up, 11 (44%) initiated ART 4–91 days after completion of
TB treatment. A high proportion of TB patients (24/90, 27%) did
not initiate ART during TB treatment despite referral and
presentation at an ART clinic for assessment.
In univariate analyses (table 2), the following were significantly
associated with not initiating ART during TB treatment: male
gender, younger age (,36 years), history of previous TB,
absence of extra-pulmonary TB, and knowing the results of drug
susceptibility testing at TB diagnosis. Using our logistic
regression model (table 2), we found that male gender
(OR= 3.7, 95%CI: 1.25–10.95) and younger age (OR= 3.3,
95%CI: 1.12–9.69) remained statistically significant (Model
P = 0.003, R2 = 0.224). The odds of not initiating ART was 12
times greater in a young man (,36 years) as compared to an
older woman ($36 years). Forty-six percent (15/28) of eligible
young men did not initiate ART as compared to 5% (1/19) of
eligible older women.
Mortality
Fifteen TB patients died during TB treatment. In univariate
analyses (table 3), the following were significantly associated with
death during TB treatment: younger age (,36 years), CD4+ count
,100 cells/mL, not presenting to an ART clinic for assessment,
not initiating ART, experiencing clinical deterioration, and
admission to hospital. Using our logistic regression model
(table 3), only a CD4+ count ,100 cells/mL remained statistically
significant (OR=18.0, 95%CI: 1.55–210.62; Model P = 0.012,
R2= 0.287).
Figure 1. Flow-diagram showing inclusion criteria and outcomes of 100 eligible patients. ART: antiretroviral treatment, TB: tuberculosis,
WHO: World Health Organisation, *11 of these 34 patients initiated antiretroviral treatment 4 to 91 days after completion of TB treatment.
doi:10.1371/journal.pone.0019484.g001
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Estimated burden due to increase in CD4+ threshold
from 200 to 350 cells/mL
When the threshold CD4+ count for ART initiation is adjusted
from less than 200 cells/mL to less than 350 cells/mL, according to
the new South African guidelines that were implememented 6
months after completion of this study, the number of eligible TB
patients requiring ART increases by 24% (95% CI: 16–32%) –
from 111 to 138 patients (figure 2).
Discussion
Timely initiation of ART in eligible HIV-infected TB patients is
a priority in South Africa. Knowing which barriers prevent ART
initiation, as well as the treatment gap among eligible TB patients,
is invaluable information for TB and HIV policy-makers who
facilitate ART provision. In this study, we found that one-third of
eligible TB patients did not initiate ART during TB treatment.
Our rate of ART initiation (66% during the first 6 months after
initiating TB treatment) is higher than reported elsewhere in South
Africa [12] – we attribute this to the close physical proximity of
our ART and TB clinics. Over the past few years, interventions at
our facility have integrated ART and TB services [13]. These
interventions include high rates of voluntary counseling and testing
of HIV status, testing of CD4+ counts at HIV diagnosis, and
expedited referral to ART services. We found that one-third of
eligible patients did not initiate ART during TB treatment, despite
the close proximity of our TB and ART services. We believe that
our ART initiation rates, while laudable, could be further
improved.
In our study, younger age and male gender increased the odds
of not initiating ART during TB treatment. To our knowledge, no
studies have reported this significant association. Previous studies
have mostly reported findings from HIV cohorts, where it has
been shown that male gender is associated with substantial
problems during ART. A Malawian study found that male gender
and a WHO stage 4 disease increased the risk of early death
during ART [14]. Similarly, Cornell et al found that men
experienced higher early mortality on ART compared to women,
largely due to their presentation with more advanced HIV disease
[15]. Recently, a Nigerian study reported that death is significantly
associated with younger age and male gender, independent of a
low CD4+ count[16] – risk factors for not initiating ART,
however, were not investigated. While men are at higher risk than
women to default ART [17], one study reported no substantial sex
differences in the benefits of ART [18]. In our study, while many
presented to the ART clinic for assessment, young men were at
greatest risk of not initiating ART. It appears that these young
men missed an ideal opportunity to initiate ART. Reasons for this
failure need to be determined and addressed. Possible explanations
include apathy[19], social stigma, lack of insight, lower socio-
economic status and poor social support networks. An alternate
explanation is that initiation of ART is more socially acceptable
among women and older men. Further studies are needed to
Table 1. Baseline characteristics and microbiologic
confirmation of tuberculosis in 100 HIV-1 infected patients
eligible for ART and receiving TB treatment.
Male gender, n (%) 54 (54)
Age ,36 years, n (%) 55 (55)
CD4+ count ,100 cells/mL 70 (70)
TMP-SMX chemoprophylaxis, n (%) 95 (95)
Previous tuberculosis, n (%) 30 (30)
Diagnosis of TB at hospital, n (%) 55 (55)
No extra-pulmonary tuberculosis, n (%) 56 (56)
Drug susceptibility test results known at TB diagnosis, n (%) 23 (23)
Drug sensitive M.tb known at TB diagnosis, n (%) 20 (20)
Drug susceptibility test results known at 6 months, n (%) 53 (53)
Drug sensitive M.tb at 6 months, n (%) 47 (47)
Weight less than 50 kilograms (%) 30 (30)
Experienced clinical deterioration, n (%) 66 (66)
Admission to hospital, n (%) 50 (50)
ART: antiretroviral treatment, TB: tuberculosis, WHO: World Health Organisation.
ART: antiretroviral treatment, TB: tuberculosis, TMP-SMX chemoprophylaxis:
daily trimethoprim-sulfamethoxazole chemoprophylaxis 160/800 mg, M.tb:
Mycobacterium tuberculosis.
doi:10.1371/journal.pone.0019484.t001
Table 2. Univariate analysis and logistic regression model showing factors associated with not initiating ART during TB treatment.
No ART (n=34) ART (n=66) P-value aOR (95%CI) P-value
Male gender, n (%) 24 (71) 30 (45) 0.017* 3.7 (1.25–10.95) 0.018*
Age ,36 years, n (%) 24 (71) 31 (47) 0.025* 3.3 (1.12–9.69) 0.031*
CD4+ count .100 cells/mL, n (%) 14 (41) 16 (24) 0.080 1.6 (0.54–4.87) 0.384
No TMP-SMX chemoprophylaxis, n (%) 3 (9) 2 (3) 0.208 2.4 (0.84–7.08) 0.102
Previous tuberculosis, n (%) 16 (47) 14 (21) 0.008* 3.2 (0.33–31.68) 0.311
Diagnosis of TB at clinic, n (%) 21 (62) 33 (50) 0.264 1.9 (0.47–7.32) 0.378
No extra-pulmonary tuberculosis, n (%) 24 (71) 32 (48) 0.035* 2.3 (0.73–7.53) 0.151
Drug susceptibility test results known at TB diagnosis, n (%) 13 (38) 13 (20) 0.045* 2.1 (0.67–6.39) 0.209
Weight less than 50 kilograms 13 (38) 17 (26) 0.214 1.1 (0.35–3.61) 0.851
No clinical deterioration, n (%) 14 (41) 20 (30) 0.277 2.2 (0.73–6.86) 0.158
Admission to hospital, n (%) 18 (53) 32 (48) 0.673 2.6 (0.70–9.50) 0.155
*P,0.05 considered statistically significant, Model likelihood ratio: P = 0.003, R2 = 0.2235.
aOR: adjusted odds ratio, 95% CI: 95% confidence interval, ART: antiretroviral treatment, TB: tuberculosis, TMP-SMX chemoprophylaxis: daily trimethoprim-
sulfamethoxazole chemoprophylaxis 160/800 mg.
doi:10.1371/journal.pone.0019484.t002
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elucidate which of these factors prevent young adult men from
initiating ART during TB treatment.
Our study has a number of strengths. Firstly, our cohort is
comparable to other TB cohorts in South Africa: these cohorts
share similar demographic profiles[8,20], socio-economic sta-
tus[9], rates of voluntary counselling and testing for HIV-1
infection (.80%)[8,personal communication – Judy Caldwell,
Cape Town Health Department], rates of HIV/TB co-infection
(.70%)[8,21], distribution of CD4+ counts at TB diagnosis
(CD4+ counts from 1-200, 201–350 and .350 cells/mL of 64%,
18% and 17%, respectively)[8, personal communication – Judy
Caldwell, Cape Town Health Department], and proportion of
HIV-1 infected patients with TB that die (15%)[8,22]. Secondly,
in this study, we recorded a number of unique variables not
routinely available in electronic TB registers in South Africa,
which we incorporated in our logistic regression models. These
unique variables included drug susceptibility results, occurrence of
clinical deterioration, presentation at the ART clinic for
assessment, initiation of ART and admission to hospital during
treatment.
We also found that TB patients with a history of previous TB
were less likely to present to an ART clinic for assessment. This
finding is disconcerting, especially as these patients presented to
health-care facilities on a daily basis for streptomycin injections,
and could have been referred to ART services by health-care
providers. To overcome this problem, ART counselling should be
offered to all HIV-infected TB patients at each clinic visit. We also
found that a CD4+ count less than 100 cells/mL was the only
significant risk factor for death, regardless of whether ART was
initiated or not. This recapitulates the importance of ART
initiation in patients with tuberculosis, prior to severe immune-
suppression.
We recognise certain limitations in this study. The proportion of
eligible patients referred to ART clinics was not ascertained.
Table 3. Univariate analysis and logistic regression model showing factors associated with death during TB treatment.
Died (n =15) Alive (n=85) P-value aOR (95%CI) P-value
Male gender, n (%) 11 (73) 43 (51) 0.103 4.0 (0.77–20.77) 0.099
Age ,36 years, n (%) 12 (80) 43 (51) 0.035* 3.8 (0.76–18.94) 0.103
CD4+ count ,100 cells/mL, n(%) 14 (93) 56 (66) 0.032* 18.0 (1.55–210.62) 0.021*
No TMP-SMX chemoprophylaxis, n (%) 2 (13) 3 (4) 0.108 15.8 (0.49–506.22) 0.118
Previous tuberculosis, n (%) 5 (33) 25 (29) 0.760 3.5 (0.57–21.21) 0.177
Diagnosis of TB at hospital, n (%) 9 (60) 41 (48) 0.401 1.2 (0.25–5.39) 0.839
No extra-pulmonary tuberculosis, n (%) 8 (53) 48 (56) 0.822 1.5 (0.31–6.89) 0.631
Drug susceptibility test results known at TB
diagnosis, n (%)
6 (40) 20 (24) 0.180 1.3 (0.28–6.39) 0.724
Weight less than 50 kilograms (%) 6 (40) 24 (29) 0.375 1.1 (0.35–3.61) 0.851
Did not present to ART clinic for assessment 4 (27) 6 (7) 0.012* 2.2 0.29–16.27 0.448
ART not initiated, n (%) 9 (60) 25 (29) 0.021* 3.6 (0.70–18.36) 0.124
Experienced clinical deterioration, n (%)** 15 (100) 51 (60) 0.047*
Admission to hospital, n (%)** 15 (100) 35 (41) 0.006*
*P,0.05 considered statistically significant;
**both the following variables were collinear, and omitted from the model: admission to hospital and experienced clinical deterioration; Model likelihood ratio:
P = 0.012, R2 = 0.287; aOR: adjusted odds ratio, 95% CI: 95%. confidence interval, ART: antiretroviral treatment, TB: tuberculosis, TMP-SMX chemoprophylaxis: daily
trimethoprim- sulfamethoxazole chemoprophylaxis 160/800 mg.
doi:10.1371/journal.pone.0019484.t003
Figure 2. Flow-diagram showing eligible patients according to new South African antiretroviral treatment guidelines [25].
doi:10.1371/journal.pone.0019484.g002
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However, we observed that .95% of adults knew their HIV
status[8], ,99% of HIV-infected TB adults had CD4+ counts
performed at TB diagnosis, and 90% of eligible TB patients
presented to ART clinics for assessment. We were unable to
determine whether early or late ART during TB treatment is more
beneficial, and await the findings of larger trials to answer this
question[23]. We acknowledge that in other parts of Africa, where
greater geographical distances exist between TB and ART clinics,
obstacles to ART initiation may differ[24]. We note that 11
eligible TB patients were not included in our analyses as they were
lost to follow-up. If these 11 TB patients are included, the
proportion that did not initiate ART increases from 34% (34/100)
to 41% (45/111). We also acknowledge that we were unable to
address other socio-demographic barriers as these data were not
collected prospectively.
Finally, with the recent change in national guidelines to increase
the CD4+ count threshold for ART [25], we anticipate a
substantial increase (by 24%) in the number of eligible TB
patients requiring ART.
Conclusion
In a clinic with integrated tuberculosis and HIV services, one-
third of eligible TB patients – particularly young men – did not
initiate ART. Research is needed to determine why eligible young
men are at greatest risk of not initiating ART. It is our hope that
further characterisation of these factors will result in strategies to
increase ART initiation during TB therapy.
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